In a Large HIV Group, Only 36% of Those Needing Statins Received Statins

November 9, 2017

Among 450 HIV-positive people with a statin indication by current guidelines, only 161 (36%) received a statin in an analysis of 1,085 people at a St. Louis HIV clinic. Potential statin-antiretroviral interactions did not explain low statin use.

Appropriate statin therapy curbs the risk of atherosclerotic cardiovascular disease (ASCVD), which poses a continuing threat to people living with HIV. Research has shown that HIV-positive populations eligible for statins by older Adult Treatment Panel (ATP) III guidelines often did not receive these drugs. Clinicians at Washington University, St. Louis, conducted a retrospective analysis to determine how many of their HIV-positive patients who were eligible for statins by 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines took statins.

The analysis focused on 1,085 HIV-positive people at least 40 years old and in care at the Washington University Virology Clinic from January through December 2015. Researchers classified them into four statin-benefit groups:

  1. Clinical ASCVD.
  2. Primary hyperlipidemia: low-density lipoprotein (LDL) cholesterol at or above 190 mg/dL.
  3. 40 to 75 years old without ASCVD but with diabetes and LDL 70 to 189 mg/dL.
  4. 40 to 75 years old without ASCVD or diabetes, with LDL 70 to 189 mg/dL, and with 10-year ASCVD risk at or above 7.5%.

The 1,085 study participants averaged 51.9 years in age; 71% were men, and 68% were black. Almost everyone (98%) was taking antiretroviral therapy, and 86% had an undetectable viral load. Most people (56%) had hypertension, while 16% had diabetes, and 9% had chronic kidney disease. Almost half (45%) smoked.

Of the 1,085 people analyzed, 450 (41%) had a statin indication, including 121 (27%) in group 1, 9 (2%) in group 2, 107 (24%) in group 3, and 213 (47%) in group 4. Of those 450 people needing a statin by 2013 ACC/AHA guidelines, only 161 (36%) took a statin, including 36% in group 1, 44% in group 2, 49% in group 3, and 29% in group 4. Proportions of people taking more effective high-dose statins were 30% in group 1, 75% in group 2, 29% in group 3, and 21% in group 4.

Compared with people not taking a statin, those who did had a higher median CD4 count (630 versus 537 cells/mm3, P = .050) and a trend toward a higher HIV suppression rate (93% versus 88%, P = .073). However, statin users did not differ from nonusers in rates of chronic kidney disease or end-stage renal disease, in proportion taking more than five antiretrovirals, in median number of total medications, or in use of antiretrovirals that may interact with statins (ritonavir [Norvir], cobicistat [Tybost], efavirenz [Sustiva, Stocrin]).

The Washington University team surmised that inconsistent use of ACC/AHA guidelines by HIV clinicians explains the gap in statin prescribing. They underline "a need to prioritize ASCVD prevention in the care of the aging HIV-infected population."

Mark Mascolini writes about HIV infection.

Related Stories

Substantial Statin Treatment Gap Exists for People Living With HIV
Less Than Half of People With HIV Who Are Eligible for Statins Receive Them
Low Vitamin D Tied to Statin-Related Muscle Toxicity in People With HIV

This article was provided by TheBodyPRO. It is a part of the publication IDWeek 2017.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.